Distinctive Cytokines as Biomarkers Predicting Fatal Outcome of Severe Staphylococcus aureus Bacteremia in Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  van den Berg, Sanne ^a   Laman, Jon D ^a   Boon, Louis ^b   ten Kate, Marian T ^a   de Knegt, Gerjo J ^a   Verdijk, Rob M ^a   Verbrugh, Henri A ^a   Nouwen, Jan L ^a   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BIOCEROS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; FATALITY; FEMALE; HISTOPATHOLOGY; INOCULATION; KERATINOCYTE; LD 50; MOUSE; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS;

ANIMALS; BACTEREMIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; MICE; MICE, INBRED BALB C; SPECIFIC PATHOGEN-FREE ORGANISMS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84874760139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059107     Document Type: Article

References (39)

1. Lowy FD, (1998) Staphylococcus aureus infections. N Engl J Med 339: 520-532.
2. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
3. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, et al. (2006) Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med 34: 2588-2595.
4. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256.
5. Pepys MB, Baltz ML, (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34: 141-212.
6. Lausevic Z, Vukovic G, Stojimirovic B, Trbojevic-Stankovic J, Resanovic V, et al. (2010) Kinetics of C-reactive protein, interleukin-6 and-10, and phospholipase A2-II in severely traumatized septic patients. Vojnosanit Pregl 67: 893-897.
7. Pepys MB, Hirschfield GM, (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812.
8. Vigushin DM, Pepys MB, Hawkins PN, (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91: 1351-1357.
9. Meisner M, (2002) Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 323: 17-29.
10. Beutler B, Milsark IW, Cerami AC, (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871.
11. Mathison JC, Wolfson E, Ulevitch RJ, (1988) Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81: 1925-1937.
12. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC, (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550-552.
13. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664.
14. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA, (1991) A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 5: 338-343.
15. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273: 934-941.
16. Cohen J, Carlet J, (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24: 1431-1440.
17. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, et al. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843.
18. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, et al. (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12-21.
19. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, et al. (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25: 1115-1124.
20. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, et al. (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733-742.
21. Dandona P, Nix D, Wilson MF, Aljada A, Love J, et al. (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79: 1605-1608.
22. van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF, (1997) Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 175: 118-122.
23. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, et al. (2000) Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis. Infect Immun 68: 1942-1945.
24. Balc IC, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B, (2003) Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 7: 85-90.
25. Mathiak G, Neville LF, Grass G, Boehm SA, Luebke T, et al. (2001) Chemokines and interleukin-18 are up-regulated in bronchoalveolar lavage fluid but not in serum of septic surgical ICU patients. Shock 15: 176-180.
26. Arnalich F, Lopez J, Codoceo R, Jim nez M, Madero R, et al. (1999) Relationship of plasma leptin to plasma cytokines and human survivalin sepsis and septic shock. J Infect Dis 180: 908-911.
27. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, et al. (2000) Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 28: 1276-1282.
28. Seishima M, Kato G, Shibuya Y, Matsukawa S, (2009) Cytokine profile during the clinical course of toxic shock syndrome. Clin Exp Dermatol 34: e632-635.
29. Cohen J, Abraham E, (1999) Microbiologic findings and correlations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis 180: 116-121.
30. Gogos CA, Drosou E, Bassaris HP, Skoutelis A, (2000) Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181: 176-180.
31. Ziebandt AK, Kusch H, Degner M, Jaglitz S, Sibbald MJ, et al. (2010) Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. Proteomics 10: 1634-1644.
32. van den Berg S, Bowden MG, Bosma T, Buist G, van Dijl JM, et al. (2011) A multiplex assay for the quantification of antibody responses in Staphylococcus aureus infections in mice. J Immunol Methods 365: 142-148.
33. De Steenwinkel JE, De Knegt GJ, Ten Kate MT, Van Belkum A, Verbrugh HA, et al. (2009) Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 22: 723-734.
34. Reichelt ME, Ashton KJ, Tan XL, Mustafa SJ, Ledent C, et al. (2011) The adenosine A(2A) receptor- Myocardial protectant and coronary target in endotoxemia. Int J Cardiol.
35. Bozic CR, Kolakowski LF Jr, Gerard NP, Garcia-Rodriguez C, von Uexkull-Guldenband C, et al. (1995) Expression and biologic characterization of the murine chemokine KC. J Immunol 154: 6048-6057.
36. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, et al. (2009) Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J 23: 3393-3404.
37. Ashare A, Powers LS, Butler NS, Doerschug KC, Monick MM, et al. (2005) Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Physiol 288: L633-640.
38. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG, (2007) Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol 179: 623-630.
39. Johansson D, Shannon O, Rasmussen M, (2011) Platelet and neutrophil responses to gram positive pathogens in patients with bacteremic infection. PLoS One 6: e26928.